淋巴细胞白血病 (CLL) 的临床结果差异很大。这项观察性研究的目的是探讨测量血浆半乳糖凝集素 9 和 CXCL-13 浓度作为 CLL 活动、预后和治疗反应早期指标的预测因子的临床价值。将这些生物标志物与其他预后指标、无进展生存期 (PFS)、首次治疗时间 (TTT) 以及随访期（4 年）内的总生存期 (OS) 进行比较。首先，分析了 CLL 患者和健康对照者诊断时的血浆半乳糖凝集素 9 和 CXCL-13 浓度。与对照组相比，CLL 患者的 CXCL-13 和半乳糖凝集素-9 血清水平显着升高。其次，我们观察到可溶性CXCL-13和半乳糖凝集素9水平较高的CLL患者临床分期较晚，预后较差，17p del，PFS短，TTT短，治疗抵抗。 CXCL-13、β2-微球蛋白、LDH、CD38%和高级别Rai阶段的水平均与半乳糖凝集素9水平密切相关。可溶性CXCL-13和galectin-9在检测CLL疾病进展和高危患者方面具有非常好的特异性和敏感性，其中galectin-9优于CXCL-13。尽管这两种生物标志物在预测 TTT 和治疗反应方面相同，但可溶性 CXCL13 在预测 OS 方面更胜一筹。 CLL 诊断后的高 CXCL-13 和半乳糖凝集素-9 血浆水平与疾病活动性、进展、晚期临床分期、短 PFS、短 TTT 和不利的治疗反应相关。© 2023。作者。

The clinical outcome of lymphocytic leukemia (CLL) is quite heterogeneous. The purpose of this observational study was to investigate the clinical merit of measuring plasma galectin-9 and CXCL-13 concentrations as predictors of CLL activity, prognosis, and early indicators of therapeutic response. These biomarkers were compared with other prognostic indicators, progression-free survival (PFS), time to first treatment (TTT), and overall survival (OS) over a follow-up period (4 years). First, plasma galectin-9 and CXCL-13 concentrations were analyzed in CLL patients at the time of diagnosis as well as healthy controls. Compared to controls, CLL patients had significantly higher serum levels of CXCL-13 and galectin-9. Second, we observed that CLL patients with high soluble CXCL-13 and galectin-9 levels had advanced clinical stages, poor prognosis, 17p del, short PFS, short TTT, and therapy resistance. The levels of CXCL-13, β2-microglobulin, LDH, CD38%, and high grade of Rai-stage were all strongly correlated with the galectin-9 levels. Soluble CXCL-13 and galectin-9 had very good specificity and sensitivity in detecting CLL disease progression and high-risk patients with the superiority of galectin-9 over CXCL-13. Although the two biomarkers were equal in prediction of TTT and treatment response, the soluble CXCL13 was superior in prediction of OS. High CXCL-13 and galectin-9 plasma levels upon CLL diagnosis are associated with disease activity, progression, advanced clinical stages, short periods of PFS, short TTT, and unfavorable treatment response.© 2023. The Author(s).